最新的RAC Regulatory Affairs Certification認證 RAC-US考試題庫

問題1

In which section of the ICH Common Technical Document will the overview of clinical data appear?

A. Module 2

B. Module 4

C. Module 1

D. Module 3

正確答案: A

問題2

During routine surveillance, a regulatory authority sent a company the following communication: "Hepatotoxicity and suicidal behavior were identified as potential safety issues for the company's product. The regulatory authority is evaluating these issues to determine the need for any regulatory action." Which action would be the most appropriate
FIRST step for the company to take?

A. Contact the regulatory authority to argue that its conclusions are wrong.

B. Repeat the Hepatotoxicity tests and send the results to the regulatory authority.

C. Contact the regulatory authority to discuss its findings.

D. Wait for the regulatory authority's final publication on its findings.

正確答案: C

問題3

In preparation for the development of a new line of products, a regulatory affairs professional is asked to prepare a short presentation for senior management. Which of the following topics is MOST important to cover?

A. Capacity of the manufacturing facilities to fully produce the new product

B. Regulatory requirements for labeling and packaging

C. Previous actions taken by regulatory authorities on similar products

D. Potential clinical sites for the Phase III clinical trial

正確答案: C

問題4

During an audit of a contract manufacturing facility by a potential client, the auditor requested to be left alone in the records room. The records room contains information on all products produced by the contract manufacturer.
Which action is MOST appropriate for the regulatory affairs professional to take?

A. Allow the auditor access to the room and records due to the current audit.

B. Deny the auditor access to the room and retrieve only the requested records.

C. Allow the auditor accompanied access to the room to retrieve the records.

D. Deny the auditor access to the room and records due to confidentiality concerns.

正確答案: C

問題5

In order to develop a global drug product, what is the MOST important environmental characteristic to consider in the country of intended use?

A. Product stability

B. Product formulation

C. Product registration

D. Product requirements

正確答案: A

問題6

A global company has obtained a patent in a specific country for a newly marketed product.
What would be the BEST advice In order to protect the patent in other countries?

A. File patents of interest in target countries.

B. File design patents in target countries.

C. Use the community patent system.

D. Use the Madrid system.

正確答案: A

問題7

One month prior to the anticipated approval date for your product, the marketing application that you submitted to a major regulatory authority has become the subject of an advisory committee meeting of experts convened by the regulatory authority. The advisory committee members unanimously vote not to approve your product because of a safety concern. Two days after the advisory committee meeting, the regulatory authority requests additional information to support the safety of your product. Assuming you have no additional data to provide, which of the following would be your MOST appropriate response to the regulatory authority's request?

A. "We disagree with the advisory committee's decision because the committee neglected the thorough safety analysis that we provided."

B. "We have no additional information to provide at this time, but we can perform an additional analysis for a specific safety concern, if necessary."

C. "We have no additional information to provide at this time because we have already provided everything needed to support our product's approval."

D. "Given the advisory committee's unanimous decision, we know that the product will not be approved, and additional data will not make any difference."

正確答案: B

問題8

When applying for marketing approval of a drug for a rare disease, which requirement can be waived?

A. Phase III clinical trials

B. Pre-clinical studies

C. Phase I clinical trials

D. Phase I and II clinical trials

正確答案: A

問題9

What is the BEST approach to ensure that raw materials, services, and sub-contractors at the level of the vendors comply with GMP requirements?

A. Request an inspection from a regulatory authority.

B. Document and perform audits.

C. Ask the vendor to take responsibility.

D. Request documentation from the sub-contractor.

正確答案: B

問題10

Who has the PRIMARY responsibility for recall of products with quality defects?

A. Consumer

B. Regulatory authority

C. Manufacturer

D. Distributor

正確答案: C

最新的RAPS Regulatory Affairs Certification (RAC) US - RAC-US免費考試真題

最新更新

站內鏈接

聯系我們